Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
Treace Medical Concepts, Inc. announced the successful completion of the first surgical cases using its new SuperBite™ Compression Screw System, designed for a wide range of foot and ankle procedures. This new system features advanced compression technology and streamlined insertion, expanding Treace's market-leading portfolio and increasing its addressable market and customer base. Full commercialization is expected in the third quarter of 2026, with Dr. Anne Holly Johnson praising its effectiveness.
New foot-and-ankle screw reaches first surgeries before Q3 launch
Treace Medical Concepts has announced the successful completion of the first surgical cases using its new SuperBite™ Compression Screw System, designed for a broad range of foot and ankle applications. Full commercialization is expected in Q3 2026, and this system, along with another planned product launch, is projected to increase Treace's total addressable market by an estimated $300 million. Despite this positive product news, the company's stock (TMCI) saw a negative market reaction, continuing a pattern of declines following recent announcements.
Treace Medical Concepts, Inc. (TMCI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Treace Medical Concepts, Inc. (NASDAQ:TMCI) securities prior to May 8, 2023. The investigation aims to determine if Treace Medical and its officers engaged in corporate wrongdoing. Investors are encouraged to contact the law firm to learn more and assist with the investigation, with no direct cost to them as the firm operates on a contingency fee basis.
TMCI PE Ratio & Valuation, Is TMCI Overvalued
Treace Medical Concepts, Inc (TMCI) is currently considered undervalued based on its forward PS ratio of 0.42 compared to its five-year average. The fair price is estimated between $29.84 to $52.43, significantly higher than its current $1.45. While competitor analysis shows TMCI's P/S ratio is much lower than the industry average, its negative revenue growth suggests this discount might be justified.
CFO at Treace Medical (TMCI) granted 100,000 performance stock units
Treace Medical Concepts, Inc. (TMCI) Chief Financial Officer Mark Hair was granted 100,000 performance stock units (PSUs) following the Compensation Committee's certification of a performance goal. These PSUs will vest in tranches of 25% on April 15, 2026, and then annually on February 15 from 2027 to 2029, contingent on his continued service. Following this grant, Hair directly holds 963,549 shares of common stock, which includes 811,691 restricted stock units.
Bronstein, Gewirtz & Grossman, LLC Encourages Treace Medical Concepts, Inc. (TMCI) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Treace Medical Concepts, Inc. (NASDAQ:TMCI) on behalf of investors who purchased its securities prior to May 8, 2023, and continue to hold them. The investigation focuses on whether the company and its officers engaged in corporate wrongdoing. Shareholders are encouraged to visit the firm's website for more information and to assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medical Concepts, Inc. (TMCI) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (NASDAQ:TMCI) regarding potential corporate wrongdoing. The firm is encouraging shareholders who purchased Treace Medical securities before May 8, 2023, and still hold them, to connect with the firm to assist in the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis and seeks to restore investor capital and ensure corporate accountability.
Treace Medical Concepts (TMCI) price target decreased by 10.94% to 3.63
The article reports that the price target for Treace Medical Concepts (TMCI) has been reduced by 10.94%, setting the new target at $3.63. This adjustment indicates a revised outlook from analysts regarding the company's future stock valuation.
Treace Medical Concepts (TMCI) price target decreased by 10.94% to 3.63
This article reports a significant decrease in the price target for Treace Medical Concepts (TMCI) stock. The new price target is set at 3.63, reflecting a 10.94% reduction. The provided content is minimal, indicating this is likely a brief financial news update.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Treace Medical Concepts, Inc. (TMCI) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Treace Medical Concepts, Inc. (TMCI) and its officers/directors. The firm is encouraging investors who purchased Treace Medical securities prior to May 8, 2023, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC, a nationally recognized firm specializing in securities fraud class actions, operates on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medical Concepts, Inc. (TMCI) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Treace Medical Concepts, Inc. (TMCI) for possible corporate wrongdoing. The firm is encouraging investors who purchased Treace Medical securities before May 8, 2023, and still hold them, to join the investigation. The legal firm operates on a contingency fee basis, meaning investors will not incur costs unless the firm is successful in recovery.
Treace Medical Concepts (Nasdaq:TMCI) - Stock Analysis
This report provides a comprehensive stock analysis of Treace Medical Concepts (Nasdaq: TMCI), a medical technology company specializing in bunion correction and foot/ankle procedures. It highlights key financial data, analyst consensus targets, growth estimates, and recent news, noting the company's current unprofitability but potential for market penetration with its innovative product portfolio. The stock is assessed to be trading at good value compared to peers despite its share price volatility and underperformance against the US medical equipment industry and overall market over the past year.
Bronstein, Gewirtz & Grossman, LLC Encourages Treace Medical Concepts, Inc. (TMCI) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Treace Medical Concepts, Inc. (NASDAQ:TMCI) on behalf of investors who purchased securities before May 8, 2023, and continue to hold them. The investigation focuses on whether Treace Medical and its officers engaged in corporate wrongdoing. The firm encourages affected stockholders to contact them for more information and to assist in the investigation without any cost to the investors.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q4 2025 earnings call transcript
This is the Q4 2025 earnings call transcript for Treace Medical Concepts, Inc. (NASDAQ:TMCI). It provides an overview of the company's financial performance and operational updates for the reported quarter. Investors and analysts can use this transcript to understand the company's strategies and outlook.
CIBC Bancorp USA Inc. Acquires New Stake in Treace Medical Concepts, Inc. $TMCI
CIBC Bancorp USA Inc. recently acquired a new stake of 18,211,522 shares, valued at approximately $122.2 million, in Treace Medical Concepts, Inc. during the third quarter, giving it a 28.58% ownership. Other institutional investors also bought or increased their holdings in the company. Treace Medical Concepts' stock metrics show a market capitalization of $94.30 million, a 52-week low of $1.31, and a 52-week high of $8.87, with analysts providing a consensus "Reduce" rating and a price target of $4.77.
Treace Medical Concepts, Inc. (TMCI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Treace Medical Concepts, Inc. (TMCI) and its officers/directors. The firm encourages stockholders who purchased Treace Medical securities before May 8, 2023, and still hold them, to contact them to learn more and assist with the investigation into these potential claims. The firm represents investors on a contingency fee basis.
Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) - June 10, 2025 Deadline to Join - Contact Levi & Korsinsky
A class action lawsuit has been filed against Treace Medical Concepts, Inc. (TMCI) alleging securities fraud between May 8, 2023, and May 7, 2024. The lawsuit claims that the company made false statements regarding competition impacting demand for its Lapiplasty product and the need to accelerate alternative product offerings. Shareholders who suffered losses during this period have until June 10, 2025, to join the class action by contacting Levi & Korsinsky, LLP.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Average Recommendation of "Reduce" from Analysts
Treace Medical Concepts, Inc. (NASDAQ:TMCI) has received a consensus "Reduce" recommendation from analysts, with an average 12-month price target of $4.77. The stock opened at $1.46, trades below its moving averages, and has a negative PE ratio. Institutional investors have significantly adjusted their holdings in the company.
How Treace Medical Concepts Inc. (TMCI) Affects Rotational Strategy Timing
This article analyzes Treace Medical Concepts Inc. (TMCI) through the lens of rotational strategy timing, providing insights from AI models. It details three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, and offers access to real-time signals and personalized alerts for subscribers.
Treace Medical (TMCI) legal chief reports routine tax share withholding
Scot Michael Elder, Chief Legal & Compliance Officer of Treace Medical Concepts, reported routine tax share withholdings on two separate dates in March. A total of 1,850 common shares were delivered to cover tax obligations, not through open-market sales. Following these transactions, Elder directly holds 794,936 common shares, which include restricted stock units.
[Form 4] TREACE MEDICAL CONCEPTS, INC. Insider Trading Activity
This article details an insider trading activity report (Form 4) for Treace Medical Concepts, Inc. filed by director and CEO John T. Treace. The report indicates routine share withholding for tax obligations on equity awards, not open-market sales, with a total of 7,083 shares disposed of. Following these transactions, John T. Treace directly owns 7,004,550 common shares, with additional footnotes clarifying beneficial ownership of certain restricted stock units and shares held by his spouse or in trusts.
Treace Medical Concepts (TMCI) executive has 1,797 shares withheld for taxes
Treace Medical Concepts' Chief Innovation Officer, Sean F. Scanlan, had 1,797 shares of common stock withheld for tax obligations on March 8 and March 10, 2026. These shares were not sold on the open market but disposed of to cover tax liabilities associated with equity compensation. Following these transactions, Scanlan directly holds 704,677 shares, including restricted stock units.
Bronstein, Gewirtz & Grossman, LLC Encourages Treace Medical Concepts, Inc. (TMCI) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Treace Medical Concepts, Inc. (TMCI) securities prior to May 8, 2023. The firm is looking into whether Treace Medical and its officers engaged in corporate wrongdoing. Investors are encouraged to contact the firm for more information regarding the ongoing securities investigation.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Treace Medical Concepts, Inc. (TMCI) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (TMCI) following allegations of corporate wrongdoing. The firm is encouraging investors who purchased Treace Medical securities before May 8, 2023, and still hold them, to join their investigation. This investigation aims to restore investor capital and ensure corporate accountability.
Treace Medical Concepts (NASDAQ:TMCI) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded Treace Medical Concepts (NASDAQ:TMCI) from "hold" to "sell," aligning with other analysts who have cut ratings and price targets, resulting in a consensus "Reduce" rating and a $4.77 target price. Following this news, the stock dropped 10.8% and is trading near its 52-week low. Despite meeting revenue and EPS estimates in its latest quarterly report, the company remains unprofitable and institutional investors own approximately 84% of its shares.
TMCI Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Treace Medical Concepts, Inc. (TMCI) based on fiscal year 2025 data, including income statements, balance sheets, and cash flow statements, along with key financial ratios. It indicates that TMCI reported $212.7M in revenue with 1.6% year-over-year growth but generated a net loss of -$59.0M, highlighting low profitability and low earnings quality. Despite strong liquidity and conservative leverage, the company faces challenges with negative operating cash flow, a short cash runway, and weak interest coverage, resulting in a moderate overall financial health score of 44/100 and a weak Piotroski F-Score.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q4 2025 Earnings Call Transcript
Treace Medical Concepts (NASDAQ: TMCI) reported its Q4 and full-year 2025 earnings, highlighting a transformational year focused on expanding its bunion solutions portfolio beyond Lapiplasty. The company provided a 2026 revenue outlook of $200 million to $212 million, representing a decline of 6% to 0% due to ongoing economic headwinds and product mix shifts, but anticipates returning to top-line growth in Q4 2026. Treace Medical also demonstrated significant improvements in adjusted EBITDA and cash burn reduction in 2025, with further reductions expected for 2026, driven by strategic product launches and disciplined cost management.
Lake Street Capital Issues Pessimistic Forecast for Treace Medical Concepts (NASDAQ:TMCI) Stock Price
Lake Street Capital has lowered its price target for Treace Medical Concepts (NASDAQ:TMCI) to $7.00 from $7.50, despite maintaining a "buy" rating, indicating a significant potential upside. However, overall analyst sentiment for TMCI is negative, with a "Reduce" consensus rating and an average target price of $4.77, following multiple firms cutting their targets. The stock experienced an 11% drop to $1.66, and the company continues to face unprofitability with negative net margin and return on equity, even as its quarterly revenue slightly exceeded estimates.
Treace Medical Concepts's Earnings: A Preview
Treace Medical Concepts (NASDAQ: TMCI) is set to announce its quarterly earnings on Friday, February 27, 2026, with analysts estimating an EPS of $-0.14. Investors will be looking for an earnings beat and positive guidance, as the company's past performance shows share price drops after previous earnings beats. Despite a 77.35% decline in shares over the last 52 weeks, the company exhibits strong financial health with positive revenue growth, efficient cost management, and robust ROE and ROA.
Treace Medical Concepts: Fourth Quarter Financial Results Overview
Treace Medical Concepts Inc. reported a fourth-quarter net loss of $9.4 million, or $0.12 per share after debt adjustments, outperforming analyst expectations of a $0.15 per share loss. The orthopedic device manufacturer achieved $62.5 million in revenue for the quarter. For the full fiscal year, the company posted a total loss of $59 million on $212.7 million in annual revenue and forecasts $200 million to $212 million in revenue for the upcoming year.
Treace Medical Concepts Q4 Loss Narrowing Challenges Persistent Bearish Narratives On Profitability
Treace Medical Concepts (TMCI) reported Q4 revenue of US$62.5 million and a basic EPS loss of US$0.15 for FY 2025, with full-year revenue at US$212.7 million and a US$0.93 EPS loss. While the company's Q4 loss narrowed from previous quarters in 2025, showing signs of cost discipline, it remains unprofitable, with a trailing net loss of US$59.0 million. This performance fuels ongoing debates between bullish investors, who point to the low 0.6x P/S ratio, and bearish investors, who highlight persistent losses and the lack of projected near-term profitability.
Treace Medical Concepts (NASDAQ:TMCI) Issues Quarterly Earnings Results
Treace Medical Concepts (NASDAQ:TMCI) reported its quarterly earnings, meeting analyst consensus with an EPS of ($0.15) and revenue of $62.52 million. The company shared conservative 2026 guidance, expecting revenues between $200M–$212M and a narrowed adjusted EBITDA loss, highlighting increased product offerings and improved cash flow in 2025. Despite market headwinds and a shift to lower-priced products, TMCI plans multiple new product launches in 2026 to expand its market and improve profit margins.
New bunion surgery tools show patients back walking in days
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) highlighted new product innovations and presented updated clinical study data at the 2026 ACFAS Annual Scientific Conference. Key findings from their Lapiplasty, Adductoplasty, and SpeedMTP procedures demonstrated low recurrence rates, early weight-bearing (3.7 to 8.4 days), and full radiographic union. The company also previewed new devices like SpeedTMT and Lightning system, expected to commercialize in H2 2026 and late 2026, respectively, furthering their 3D bunion solution portfolio.
TREACE MEDICAL CONCEPTS, INC. SEC 10-K Report
Treace Medical Concepts, Inc. has released its 2025 10-K report, highlighting financial and operational achievements such as $212.7 million in revenue and strategic product launches like the Nanoplasty and Percuplasty systems. The company is actively expanding its product offerings and market presence, investing in R&D and surgeon education, while also navigating challenges including competitive pressures and the need for sustained profitability. They plan to commercialize the Lapiplasty Lightning™ platform in 2026 to drive future growth.
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
Treace Medical Concepts, Inc. reported its financial results for the fourth quarter and full-year ended December 31, 2025. The company announced revenues of $29.d million for Q4 2025 and $121.f million for the full year, representing a 2% increase compared to the prior year. Despite a net loss, the company reduced its adjusted EBITDA loss by 64% and cash usage by 65% for the full year 2025.
Treace Medical Concepts (NASDAQ: TMCI) posts 2025 loss and guides flat-to-down 2026 sales
Treace Medical Concepts reported a net loss of $59.0 million for the full year 2025, with revenue up 2% to $212.7 million, though Q4 revenue declined 9% due to a sales shift towards lower-priced bunion kits. The company projects 2026 revenue to be flat-to-down by 6% ($200 million to $212 million) and anticipates an adjusted EBITDA loss of $4.0 million to $6.0 million. Despite the soft outlook, Treace reduced its cash usage by 46% in 2025 and secured a new credit facility for additional liquidity.
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
Treace Medical Concepts reported its fourth-quarter and full-year 2025 financial results, showing revenue of $62.5 million in Q4 2025 and $212.7 million for the full year, a 2% increase over 2024. The company reported a full-year 2025 net loss of $(59.0) million but reduced adjusted EBITDA loss by 64% and decreased cash usage by 46% compared to the previous year. For 2026, Treace anticipates revenue between $200 million and $212 million and expects a further 50% reduction in cash usage.
Treace Medical Concepts Q4 Earnings Summary & Key Takeaways
Treace Medical Concepts (NASDAQ: TMCI) reported its Q4 earnings, missing estimated earnings per share (EPS) by -7.14% and experiencing a $6.19 million decline in revenue year over year. The company posted an EPS of $-0.15 against an estimate of $-0.14. This report outlines the Q4 results and provides a historical overview of the company's past earnings performance in previous quarters.
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
Treace Medical Concepts (NasdaqGS: TMCI) reported its financial results for the fourth quarter and full-year ended December 31, 2025. The company generated $62.5 million in revenue for Q4 2025 and $212.7 million for the full year 2025, a 2% increase year-over-year. Despite a net loss, Treace reduced its adjusted EBITDA loss by 64% and decreased cash usage by 46% compared to the prior year.
Treace Medical Concepts, Inc. (TMCI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Treace Medical Concepts, Inc. (TMCI) on behalf of investors who purchased securities prior to May 8, 2023, and continue to hold them. The investigation concerns possible corporate wrongdoing by the company and its officers/directors. Investors are encouraged to contact the law firm for more information and to assist with the investigation, with no cost to them as the firm operates on a contingency fee basis.
Treace Medical Concepts Inc expected to post a loss of 15 cents a share - Earnings Preview
Treace Medical Concepts Inc (TMCI) is anticipated to report a loss of 15 cents per share, according to this earnings preview. This information is provided by Refinitiv and Reuters, highlighting expectations for the company's upcoming financial disclosure.
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference
Treace Medical Concepts, Inc. will showcase new product innovations and present updated clinical study data at the 2026 ACFAS Annual Scientific Conference. Key highlights include the commercialization of SpeedTMT™ Rapid Compression Implant and the Lapiplasty® Lightning™ System, alongside presentations on the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies, demonstrating positive outcomes for early weight-bearing and deformity correction. These advancements aim to strengthen Treace’s leadership in the surgical treatment of bunions and related midfoot deformities.
Treace Medical Concepts (NASDAQ:TMCI) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen upgraded Treace Medical Concepts (NASDAQ:TMCI) from "sell" to "hold," although the general analyst consensus remains "Reduce" with an average price target of $4.21. The company's shares are trading near their 12-month low, reflecting recent weakness. Treace Medical Concepts specializes in surgical solutions for foot and ankle conditions, with its Lapiplasty 3D Bunion Correction System as its flagship product.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medical Concepts, Inc. (TMCI) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Treace Medical Concepts, Inc. (NASDAQ:TMCI) on behalf of investors who purchased securities prior to May 8, 2023, and still hold them. The investigation focuses on whether the company and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information and to assist with the investigation, noting they work on a contingency fee basis.
Dispute Between Treace Medical and Fusion Orthopedics Resolved
Treace Medical Concepts, Inc. and Fusion Orthopedics, LLC have announced an amicable resolution to their litigation. The lawsuit, filed by Treace Medical, involved allegations of patent, trademark, and copyright infringement, along with unfair trade practices concerning their bunion surgery products. Fusion Orthopedics had filed counterclaims including false advertising, but both parties have now settled the matter under confidential terms.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Treace Medical Concepts, Inc. (TMCI) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (TMCI) following potential corporate wrongdoing. The firm is encouraging investors who purchased Treace Medical securities before May 8, 2023, and still hold them, to join the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Average Rating of "Reduce" by Brokerages
Treace Medical Concepts, Inc. (NASDAQ:TMCI) has received an average "Reduce" rating from six brokerages, with two recommending "sell" and four "hold", and a consensus one-year price target of $4.21. Institutional ownership is high at 84.08%, with significant recent activity from hedge funds like AQR Capital Management and Millennium Management. The stock is currently under pressure, trading at its 12-month low of $1.86 and below its 200-day simple moving average.
Treace Medical Concepts (NASDAQ:TMCI) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded Treace Medical Concepts (NASDAQ:TMCI) to a "Sell" rating, contributing to a consensus "Reduce" rating for the stock among analysts. The company's shares opened at a 12-month low of $1.86, with a market capitalization of approximately $118.5 million. Institutional investors hold about 84% of the stock, and the company is known for its Lapiplasty 3D Bunion Correction System.
Treace Medical Concepts to Release Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
Treace Medical Concepts will release its fourth-quarter and full-year 2025 financial results before the market opens on February 27, 2026, followed by a conference call at 8:00 AM ET. The company specializes in surgical treatments for bunions and midfoot deformities, leveraging its Lapiplasty® 3D Bunion Correction® System, and is expanding its product offerings and digital solutions. The announcement includes an AI summary highlighting potential positives like transparency and innovation, alongside potential negatives such as the lack of financial guidance and recent innovation details.
Treace Medical Concepts to Release Q4 and Full Year 2025 Financial Results
Treace Medical Concepts (TMCI) will release its Q4 and full year 2025 financial results before trading on February 27, 2026, followed by a conference call at 8:00 AM ET. The company is focused on the bunion and midfoot deformity treatment market, which affects approximately 67 million Americans. Treace's Lapiplasty®3D Bunion Correction System and other technologies aim to address these issues and are central to its growth strategy, despite recent analyst downgrades on its price target.
